27
Nov, 2021
The results of the study show that there is no clear advantage for adopting a shorter 5-day course, with a loading dose, over the standard 10-day course in infants under 3 months of age with severe sepsis
28
Jun, 2021
Università degli Studi di Padova, Istituto Zooprofilattico Sperimentale delle Venezie e Penta presentano nuovi dati sulla durata della protezione immunitaria contro SARS-CoV-2 nei bambini Uno studio pubblicato in questi giorni sulla rivista “Paediatrics” dimostra che i bambini affetti da forme lievi di COVID-19 sviluppano una risposta anticorpale maggiore e più duratura di quella degli adulti. Lo studio ha coinvolto 57 famiglie venete colpite dal COVID 19 e seguite presso il Dipartimento Salute della Donna e del Bambino dell’Università di Padova. Padova, 28 giugno 2021 – Ricercatori dell’Università degli Studi […]
3
Feb, 2021
Today marks the official launch of UNIVERSAL, the newly funded European-African clinical research partnership that aims to develop two antiretroviral formulations for children living with HIV and to speed up their availability at low cost for low- and middle-income countries (LMICs).
6
Feb, 2020
On 30th January 2020, the Director General of the World Health Organisation (WHO) declared the outbreak of 2019-nCoV a public health emergency of international concern. In his statement, Dr Tedros Ghebreyesus called for solidarity and cooperation to accelerate preparations and to advance knowledge on the virus and its impacts.
1
Apr, 2019
Geneva / Padova, Monday 4 March 2019 – The Global Antibiotic Research & Development Partnership (GARDP) and Penta, the paediatric infectious diseases research network, have joined forces to tackle drug-resistant infections in children. The strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines. Globally, more than three million childhood deaths result from infectious diseases, such as pneumonia and sepsis (1). Children are also particularly affected by antimicrobial resistance […]
1
Apr, 2019
Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019 The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. The purpose of VALUE-Dx is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies. VALUE-Dx is co-funded […]
